Recent Publications

Researchers affiliated with the UF Health Personalized Medicine Program advance methods for putting genomic medicine into clinical practice and contribute new pharmacogenomics discoveries to build the evidence base for future clinical implementations. Recent publications are highlighted below.

Citation Date PubMed ID
Hernandez W, Aquino-Michaels K, Drozda K, et al. Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Transl Res. 2015 Jun;165(6):651-7. Jun-15 25499099
Weng L, Quinlivan E, Gong Y, et al. Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord. 2015 Jun;13(5):195-202. Epub 2015 Feb 9. Jun-15 25664967
Chittani M, Zaninello R, Lanzani C, et al.  TET2 and CSMD1 genes affect systolic blood pressure response to hydrochlorothiazide in never treated essential hypertensives. J Hypertens. 2015;33:1301-09. Jun-15 25695618
Cavallari LH, Weitzel KM. Pharmacogenomics in cardiology – genetics and drug response: 10 years of progress. (Invited commentary) Future Cardiol. 2015 May;11(3):281-6. May-15 26021633
Langaee TY, Zhong G, Li W, et al. The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression. Pharmacogenet Genomics. 2015 May;25(5):239-45. May-15 25738370
Theofilogiannakos EK, Boudoulas KD, Gawronski  BA, et al. (MD). Floppy mitral valve/mitral valve prolapse syndrome: beta-adrenergic receptor polymorphism may contribute to the pathogenesis of symptoms. J Cardiol. 2015 May;65(5):434-8. Epub 2014 Sep 22. May-15 25172623
McDonough CW, McClure LA, Mitchell BD, et al.  CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. J Am Heart Assoc, 2015 May 27;4(6). Epub May 27. May-15 26019129
Fox CS, Hall JL, Arnett DK, et al.  Future translational applications from the contemporary genomics era: A scientific statement from the American Heart AssociationCirculation. 2015 May 12;131(19):1715-36. Epub 2015 April 16. May-15 25882488
Del-Aguila JL, Cooper-DeHoff RM, Chapman AB, et al. Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. Pharmacogenomics J. 2015 Apr;15(2):153-7. Apr-15 25201287
Drozda K, Wong S, Patel SR, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2015 Feb;25(2):73-81. Feb-15 25461246
Shroads AL, Coats BS, McDonough CW, et al. Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. J Clin Pharmacol. 2015 Jan;55(1):50-5. Jan-15 25079374
Langaee TY, Hamadeh IS, Chapman AB, et al. A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. PLoS One. 2015 Jan 27;10(1). Jan-15 25625348
Johnson JA, Hamadeh IS, Langaee TY. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies. J Natl Cancer Inst. 2015 Jan 31;107(2). Jan-15 25638249
Johnson JA, Cavallari LH.  Warfarin Pharmacogenetics. (Invited review) Trends Cardiovasc Med. 2015 Jan;25(1):33-41. Jan-15 25282448
Hiltunen TP, Donner KM, Sarin AP, et al. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26;4(1):e001521. Jan-15 25622599
Nagai R, Ohara M, Cavallari LH, et al. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015;16(3):217-25. Jan-15 25712185
Fontana V, McDonough CW, Gong Y, et al. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10;3(6):e001398. Nov-14 25385345
Cavallari LH, Duarte JD. Genes affecting warfarin response – interactive or additive? (Invited commentary) J Clin Pharmacol. 2014 Nov [Epub ahead of print]. Nov-14 25385663
Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Gums JG, Beitelshees AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums, JG, Cooper-DeHoff RM, Johnson JA. Predictors for glucose change in hypertensive participants following short-term treatment with Atenolol or hydrochlorothiazide. Pharmacotherapy 2014 Nov;34(11):1132-40. Nov-14 25202885
Daneshjou R, Gamazon ER, Burkley B, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 2014 Oct 2;124(14):2298-305. Oct-14 25079360
Patel SR, Langaee TY, Wong SS, Cavallari LH. Pyrosequencing of the CYP2C9 -1766T>C polymorphism as a means of detecting the CYP2C9*8 allele. Pharmacogenomics. 2014 Sep;15(13):1717-22. Sep-14 25410896
Hamadeh IS, Langaee TY, Dwivedi R, et al. Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate. Clin Pharmacol Ther. 2014 Aug;96(2):175-81. doi: 10.1038/clpt.2014.62. Epub 2014 Mar 17. Aug-14 24637943
Langaee TY, Zhu HJ, Wang X, et al. The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenet Genomics. 2014 Aug;24(8):381-6. doi: 10.1097/FPC.0000000000000068 Aug-14 24945780
Cavallari LH, Nutescu EA. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question. Clin Pharmacol Ther. 2014 Jul;96(1):22-4. Jul-14 24942399
Owusu Obeng A, Egelund EF, Alsultan A, et al. CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics? Pharmacotherapy. 2014 Jul;34(7):703-18. doi: 10.1002/phar.1400. Epub 2014 Feb 7. Jul-14 24510446
Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014 Jun 11. doi: 10.1038/clpt.2014.125. [Epub ahead of print] Jun-14 24918167
Hernandez W, Gamazon ER, Aquino-Michaels K, et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.Pharmacogenomics J. 2014 Jun;14(3):223-8. doi: 10.1038/tpj.2013.34. Epub 2013 Sep 10 Jun-14 24018621
Zhong G, Li W, Gu Y, et al. Chloride and other anions inhibit dichloroacetate-induced inactivation of human liver GSTZ1 in a haplotype-dependent manner. Chem Biol Interact. 2014 May 25;215:33-9. doi: 10.1016/j.cbi.2014.02.015. Epub 2014 Mar 13. May-14 24632415
Voils SA, Cooper-DeHoff RM. Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. Diabetes Metab Syndr. 2014 Apr-Jun;8(2):88-90. doi: 10.1016/j.dsx.2014.04.021. Epub 2014 May 22. May-14 24907172
Lee YM, Eggen J, Soni V, et al. Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics. 2014 May;15(7):909-14. doi: 10.2217/pgs.14.47. May-14 24956244
Johnson JA. Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation. 2012 Apr 24;125(16):1964-6. doi: 10.1161/CIRCULATIONAHA.112.100628. Epub 2012 Mar 19. PubMed Apr-14 22431866
Cooper-Dehoff RM, Hou W, Weng L, et al. Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet. 2014 Apr 1;7(2):199-205. doi: 10.1161/CIRCGENETICS.113.000421. Epub 2014 Mar 13. Apr-14 24627569
Ganesh SK, Arnett DK, Assimes TL, et al. Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation. 2013 Dec 24;128(25):2813-51. doi: 10.1161/01.cir.0000437913.98912.1d. Epub 2013 Dec 2. Mar-14 24297835
Perera MA, Cavallari LH, Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin Pharmacol Ther. 2014 Mar;95(3):242-4. doi: 10.1038/clpt.2013.209. Mar-14 24548987
Tragante V, Barnes MR, Ganesh SK, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet. 2014 Mar 6;94(3):349-60. doi: 10.1016/j.ajhg.2013.12.016. Epub 2014 Feb 20. Mar-14 24560520
Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):56-67. doi: 10.1002/ajmg.c.31390. Epub 2014 Mar 10. Mar-14 24616371
Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3. Epub 2013 Feb 12. Feb-14 23400010
Vandell AG, McDonough CW, Gong Y, et al. Hydrochlorothiazide-induced hyperuricaemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. J Intern Med. 2014 Feb 12. doi: 10.1111/joim.12215. [Epub ahead of print] Feb-14 24612202
Gong Y, McDonough CW, Beitelshees AL, et al. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb;34(2):123-30. doi: 10.1002/phar.1355. Epub 2013 Oct 9. Feb-14 24122840
Kawaguchi-Suzuki M, Frye RF. The role of pharmacogenetics in the treatment of chronic hepatitis C infection. Pharmacotherapy. 2014 Feb;34(2):185-201. doi: 10.1002/phar.1349. Epub 2013 Sep 30. Feb-14 24114761
Patel HN, Ursan ID, Zueger PM, et al. Stakeholder views on pharmacogenomic testing. Pharmacotherapy. 2014 Feb;34(2):151-65. doi: 10.1002/phar.1364. Epub 2013 Oct 24. Feb-14 24167008
Le MT, Lobmeyer MT, Campbell M, et al. Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals. PLoS One. 2013;8(1):e52062. doi: 10.1371/journal.pone.0052062. Epub 2013 Jan 14. Jan-14 23341889
Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19. Dec-13 24251361
Karnes JH, Gong Y, Pacanowski MA, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genomics. 2013 Dec;23(12):697-705. doi: 10.1097/FPC.0000000000000012. Dec-13 24128935
Kawaguchi-Suzuki M, Frye RF. Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013 Nov 26;4:147. doi: 10.3389/fphar.2013.00147. eCollection 2013. Nov-13 24324437
Nutescu EA, Drozda K, Bress AP, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013 Nov;33(11):1156-64. doi: 10.1002/phar.1329. Epub 2013 Jul 17. Nov-13 23864527
Drozda K, Labinov Y, Jiang R, et al. A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ. 2013 Oct 14;77(8):175. doi: 10.5688/ajpe778175. Oct-13 24159216
McDonough CW, Gillis NK, Alsultan A, et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013 Oct 7;8(10):e76984. doi: 10.1371/journal.pone.0076984. eCollection 2013. Oct-13 24116192
Karnes JH, McDonough CW, Gong Y, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J. 2013 Oct;13(5):430-6. doi: 10.1038/tpj.2012.34. Epub 2012 Aug 21. Oct-13 22907731
Lima JJ, Lang JE, Mougey EB, et al. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr. 2013 Sep;163(3):686-91. doi: 10.1016/j.jpeds.2013.03.017. Epub 2013 Apr 24. Sep-13 23623526
Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. Sep-13 23698643
Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5. Aug-13 23755828
Shuldiner AR, Relling MV, Peterson JF, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19. Aug-13 23588301
Turner ST, Boerwinkle E, O’Connell JR, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug;62(2):391-7. doi: 10.1161/HYPERTENSIONAHA.111.00436. Epub 2013 Jun 10. Aug-13 23753411
McDonough CW, Gong Y, Padmanabhan S, et al. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension. 2013 Jul;62(1):48-54. doi: 10.1161/HYPERTENSIONAHA.111.00823. Epub 2013 May 20. Jul-13 23690342
Duarte JD, Turner ST, Tran B, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J. 2013 Jun;13(3):257-63. doi: 10.1038/tpj.2012.4. Epub 2012 Feb 21. Jun-13 22350108
Shahin MH, Cavallari LH, Perera MA, et al. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost. 2013 Jun;109(6):1045-50. doi: 10.1160/TH12-10-0789. Epub 2013 Mar 21. Jun-13 23571513
Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease–implications for personalized medicine. Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. May-13 23686351
Johnson JA, Klein TE, Relling MV. Clinical implementation of pharmacogenetics: more than one gene at a time. Clin Pharmacol Ther. 2013 May;93(5):384-5. doi: 10.1038/clpt.2013.7. May-13 23598455
Johnson JA, Elsey AR, Clare-Salzler MJ, et al. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 2013 May;14(7):723-6. doi: 10.2217/pgs.13.59. May-13 23651020
Johnson JA. Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics. 2013 May;14(7):835-43. doi: 10.2217/pgs.13.52. May-13 23651030
Shahin MH, Johnson JA. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? Curr Opin Cardiol. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Review. May-13 23478884
Lewis JP, Ryan K, O’Connell JR, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013 Apr;6(2):184-92. doi: 10.1161/CIRCGENETICS.111.964627. Epub 2013 Feb 7. Apr-13 23392654
McDonough CW, Burbage SE, Duarte JD, et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr;31(4):698-704. doi: 10.1097/HJH.0b013e32835e2a71. Apr-13 23353631
Wikoff WR, Frye RF, Zhu H, et al. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11. Mar-13 23536766
Bress A, Patel SR, Perera MA, et al. Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics. 2012 Dec;13(16):1925-35. doi: 10.2217/pgs.12.164. Dec-12 23215885
Gong Y, McDonough CW, Wang Z, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec;5(6):686-91. doi: 10.1161/CIRCGENETICS.112.964080. Epub 2012 Oct 19. Dec-12 23087401
Johnson JA, Burkley BM, Langaee TY, et al. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther. 2012 Oct;92(4):437-9. doi: 10.1038/clpt.2012.125. Epub 2012 Aug 22. Review Oct-12 22910441
Vandell AG, Lobmeyer MT, Gawronski BE, et al. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct;60(4):957-64. doi: 10.1161/HYPERTENSIONAHA.112.198721. Epub 2012 Sep 4. Oct-12 22949529
Cavallari LH. Tailoring drug therapy based on genotype. J Pharm Pract. 2012 Aug;25(4):413-6 Aug-12 22907842
Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31. Review. Jul-12 22871196
Ashley EA, Hershberger RE, Caleshu C, et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association.Circulation. 2012 Jul 3;126(1):142-57. Jul-12 22645291
Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23. Jul-12 22617227
Shafiu M, Johnson RJ, Turner ST, et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012;35(6):477-82. doi: 10.1159/000337370. Epub 2012 Jun 8. Jun-12 22688828
Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012 Jun;44 Suppl 1:S17-22. doi: 10.3109/07853890.2011.653399. Review. Jun-12 22713143
Johnson JA, Roden DM, Lesko LJ, et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther. 2012 May;91(5):774-6. doi: 10.1038/clpt.2012.21. May-12 22513313
Wang D, Sun X, Gong Y, et al. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. Drug Metab Dispos. 2012 May;40(5):884-91. doi: 10.1124/dmd.111.044255. Epub 2012 Jan 30. May-12 22289258
Cavallari LH, Schumock GT. Cost is not a barrier to implementing clopidogrel pharmacogenetics. Pharmacotherapy. 2012 Apr;32(4):299-303. doi: 10.1002/j.1875-9114.2012.01107.x. Apr-12 22461119
Duarte JD, Zineh I, Burkley B, et al. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22;10:56. doi: 10.1186/1479-5876-10-56. Mar-12 22440088
Papp AC, Pinsonneault JK, Wang D, et al. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One. 2012;7(3):e31930. doi: 10.1371/journal.pone.0031930. Epub 2012 Mar 5. Mar-12 22403620